Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours

Table 2 Patient characteristics - advanced gastroenteropancreatic neuroendocrine tumours with and without carcinoid syndrome n (%)

	All patientsn = 50	With carcinoid syndromen = 25	Without carcinoid syndrome n = 25	P value
Age (median)	65.5	67	62	0.19
95%CI	(61.5-68.5)	(61.3-70.9)	(58.0-68.9)
Gender	F:21 (42) M:29 (58)	F:9 (36) M:16 (64)	F: 12 (48) M: 13 (52)	0.39
Median time since diagnosis (mo)	39	45	36	0.66
(95%CI)	(21.54-48.46)	(20.10-48.90)	(18.21-56)
Prior Surgery	24 (48)	9 (36)	15 (60)	0.09
Recurrent disease following previous curative intent treatment	8 (16)	3 (12)	5 (20)	0.44
Primary disease site
Stomach	1 (2)	0 (0)	1 (4)
Small bowel	29 (58)	18 (72)	11 (44)
Pancreas	11 (22)	1 (4)	10 (40)
Large bowel	3 (6)	1 (4)	2 (8)
Unknown GI tract	6 (12)	5 (20)	1 (4)
Median Ki-67
% (95%CI)	3 (2-4.8)	2 (2-5)	3 (2-7.7)	0.55
ECOG PS n (%)
0	14 (27)	7 (28)	7 (28)
1	30 (60)	16 (64)	14 (56)
2	4 (8)	1 (4)	3 (12)
3	2 (4)	1 (4)	1 (4)
Current treatment
Nil	5 (10)	2 (8)	4 (16)
Best supportive care	1 (2)	0 (0)	1 (4)
Chemotherapy	5 (10)	0 (0)	5 (20)
Interferon + Somatostatin analogue	2 (4)	2 (8)	0 (0)
Peptide receptor radionuclide Therapy	2 (4)	1 (4)	1 (4)
Peptide receptor radionuclide therapy + Somatostatin analogues	2 (4)	1 (4)	1 (4)
Somatostatin analogues	28 (56)	8 (72)	9 (36)
Tryptophan hydroxylase inhibitor + Somatostatin analogues	1 (2)	1 (4)	0 (0)
mTOR inhibitor	4 (8)	0 (0)	4 (16)
Use of psychoactive medications
Nil	44 (88)	22 (88)	22 (88)
Selective serotonin Reuptake inhibitors	3 (6)	1 (4)	2 (8)
Benzodiazepine	1 (2)	1 (4)	0 (0)
Selective serotonin reuptake inhibitors + benzodiazepine	1 (2)	0 (0)	1 (4)
Unknown	1 (2)	1 (4)	0 (0)

CI: Confidence interval; ECOG PS: Eastern Cooperative Oncology Group performance status.